Apogee Therapeutics, Inc Common Stock

Yahoo Finance • 2 days ago

Apogee Therapeutics, Inc. Announces Closing of Public Offering and Full Exercise of the Underwriters’ Option to Purchase Additional Shares for Gross Proceeds of $345 Million

SAN FRANCISCO and BOSTON, Oct. 10, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest in... Full story

Yahoo Finance • 4 days ago

Why Apogee, A Rival To Regeneron And Sanofi, Rocketed 34% And Broke Out

Shares of Apogee Therapeutics have gained 34% over the past two days as the small biotech looks to take on Regeneron and Sanofi. Continue Reading View Comments... Full story

Yahoo Finance • 4 days ago

Biggest stock movers Thursday: AZZ, RELL, and more

[Candlestick chart and data of financial market.] tadamichi Stock futures were largely unchanged in premarket trading on Thursday, following a strong tech rally that pushed the Nasdaq to a new record high in the previous session. Here ar... Full story

Yahoo Finance • 4 days ago

Apogee Therapeutics prices $300M public offering

* Apogee Therapeutics (NASDAQ:APGE [https://seekingalpha.com/symbol/APGE]) priced its public offering at $41 per share, raising ~$300M in gross proceeds. * The offering includes 6.95M common shares and 365,853 pre-funded warrants price... Full story

Yahoo Finance • 4 days ago

Apogee Therapeutics, Inc. Announces Pricing of $300 Million Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest in... Full story

Yahoo Finance • 4 days ago

Apogee Therapeutics, Inc. Announces Proposed Underwritten Public Offering

SAN FRANCISCO and BOSTON, Oct. 08, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc. (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest in... Full story

Yahoo Finance • 28 days ago

BofA Raises Apogee Therapeutics (APGE) PT to $87 Following Positive Phase 2 APEX Trial Results for Atopic Dermatitis

Apogee Therapeutics Inc. (NASDAQ:APGE) is one of the best up and coming stocks with huge upside potential. On August 28, BofA analyst Tim Anderson raised the firm’s price target on Apogee Therapeutics to $87 from $78, while keeping a Buy r... Full story

Yahoo Finance • last month

Apogee Therapeutics Announces Late-Breaker Presentation of 16-Week Data from Phase 2 APEX Trial of APG777 for Moderate-to-Severe Atopic Dermatitis at the Upcoming European Academy of Dermatology and Venereology (EADV) 2025 Congress

SAN FRANCISCO and BOSTON, Sept. 11, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing optimized, novel biologics with potential for best-in-class profiles in the largest... Full story

Yahoo Finance • last month

Apogee Therapeutics to Participate at the Stifel 2025 Virtual Immunology and Inflammation Forum

SAN FRANCISCO and BOSTON, Sept. 03, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), today announced that members of management will participate in a fireside chat at the Stifel 2025 Virtual Immunology and Inflammation... Full story

Yahoo Finance • 2 months ago

InvestingPro Fair Value model captures 43% downside in Apogee Therapeutics

In March 2024, InvestingPro’s Fair Value model identified (NASDAQ:APGE) as significantly overvalued at $66.54, challenging the prevailing bullish sentiment. Today’s analysis validates that contrarian call, with the stock trading at $38.30,... Full story

Yahoo Finance • 2 months ago

Apogee Therapeutics reports Q2 results

* Apogee Therapeutics press release [https://seekingalpha.com/pr/20195744-apogee-therapeutics-provides-pipeline-progress-and-reports-second-quarter-2025-financial] (NASDAQ:APGE [https://seekingalpha.com/symbol/APGE]): Q2 net loss was $66.... Full story

Yahoo Finance • 2 months ago

Apogee Therapeutics Provides Pipeline Progress and Reports Second Quarter 2025 Financial Results

Positive 16-week data from APEX Phase 2 Part A met all primary and key secondary endpoints for APG777, a potentially best-in-class anti-IL-13 antibody, in moderate-to-severe atopic dermatitis APEX Part A testing every 3- or 6-month mainte... Full story

Yahoo Finance • 3 months ago

Stifel reiterates Buy rating on Apogee Therapeutics stock amid positive AD data

Investing.com - Stifel has reiterated its Buy rating and $95.00 price target on Apogee (NASDAQ:APOG) Therapeutics Inc (NASDAQ:APGE) following recent Phase 2a data for its atopic dermatitis (AD) treatment APG777. According to InvestingPro d... Full story

Yahoo Finance • 3 months ago

Canaccord Genuity reaffirms Buy rating on Apogee Therapeutics stock after positive trial data

Investing.com - Canaccord Genuity has reiterated its Buy rating and $89.00 price target on Apogee (NASDAQ:APOG) Therapeutics Inc (NASDAQ:APGE) following positive clinical trial results for its atopic dermatitis treatment. The target repres... Full story

Yahoo Finance • 3 months ago

Apogee Therapeutics stock maintains Buy rating at Citi after positive data

Investing.com - Citi maintained its Buy rating and $95.00 price target on Apogee (NASDAQ:APOG) Therapeutics Inc (NASDAQ:APGE), a $2.77 billion market cap biotech company, following the release of Phase 2a data for its atopic dermatitis tre... Full story

Yahoo Finance • 3 months ago

Apogee falls after results from atopic dermatitis trial

[On the table are a stethoscope, a thermometer, a pen and a notebook with the inscription -Atopic dermatitis] Dzmitry Skazau/iStock via Getty Images Apogee Therapeutics (NASDAQ:APGE [https://seekingalpha.com/symbol/APGE]) stock fell on Mo... Full story

Yahoo Finance • 3 months ago

Apogee Therapeutics Announces Positive 16-Week Data from Phase 2 APEX Clinical Trial of APG777, its Potentially Best-in-Class Anti-IL-13 Antibody, in Moderate-to-Severe Atopic Dermatitis

APEX Part A met all primary and key secondary endpoints and exceeded trial objectives, including 71.0%decrease from baseline in EASI at Week 16 APG777 demonstrated EASI-75 of 66.9% (42.5% placebo-adjusted) at Week 16, the highest topline... Full story

Yahoo Finance • 3 months ago

Apogee Therapeutics to Host Conference Call to Report Part A 16-Week Data from the Phase 2 APEX Trial of APG777 in Patients with Moderate-to-Severe Atopic Dermatitis on July 7, 2025

SAN FRANCISCO and BOSTON, July 06, 2025 (GLOBE NEWSWIRE) -- Apogee Therapeutics, Inc., (Nasdaq: APGE), a clinical-stage biotechnology company advancing novel biologics with the potential for differentiated efficacy and dosing in the larg... Full story

Yahoo Finance • 4 months ago

Apogee Therapeutics stock maintains buy rating at Stifel ahead of data

Investing.com - Stifel reiterated its buy rating and $95.00 price target on Apogee (NASDAQ:APOG) Therapeutics Inc (NASDAQ:APGE), currently trading at $41.18 with a market cap of $2.4 billion, ahead of upcoming Phase 2a data in atopic derma... Full story

Yahoo Finance • 4 months ago

APGE Makes Bullish Cross Above Critical Moving Average

In trading on Friday, shares of Apogee Therapeutics Inc (Symbol: APGE) crossed above their 200 day moving average of $43.86, changing hands as high as $44.64 per share. Apogee Therapeutics Inc shares are currently trading up about 6.3% on... Full story